Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin

Southern Medical Journal

Volumn 99, Issue 12, 2006, Pages 1385-1387

  Khandwala, Hasnain M ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b LMC Endocrinology Centers   (Canada)

Author keywords

Antiseizure medications; CYP450; Dyslipidemia; Epilepsy; Hypolipidemic agents

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FOSINOPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHENOBARBITAL; PHENYTOIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPILEPSY; FAMILY HISTORY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MYALGIA; PHYSICAL EXAMINATION;

ANTICHOLESTEREMIC AGENTS; ANTICONVULSANTS; CHOLESTEROL, LDL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHENYTOIN;

EID: 33845952541     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000251470.39036.ea     Document Type: Article

References (13)

1. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006;113:1406-1414.
2. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005;96:54F-60F.
3. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-370.
4. Piacentini N, Trifiro G, Tari M, et al. Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 2005;61:615-620.
5. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195-1211.
6. Maxa JL, Melton LB, Ogu CC, et al. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 2002;36:820-823.
7. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(23 Suppl I):III-50-III-57.
8. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28:26-35.
9. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141-1160.
10. Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000;39:99-116.
11. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003;4:495-505.
12. Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 1999;75:359-360.
13. Lee LS, Nafziger AN, Bertino JS Jr. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther 2005;78:1-6.